Q-omics provides the consensus-scored RN7SL221P profile across patient tissues and cancer cell-line models. RN7SL221P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RN7SL221P is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, RN7SL221P RNA expression shows 12,339 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where RN7SL221P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL221P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL221P survival associations across molecular data types. RN7SL221P RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL221P RNA expression–survival associations across cancer types. High RN7SL221P expression shows unfavorable associations in LIHC, BRCA and STAD, but favorable associations in MESO, GBM and THCA. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RN7SL221P RNA expression.
This table summarizes RN7SL221P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL221P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL221P shows lower tumor expression in KICH and higher tumor expression in KIRC, LUAD, HNSC, LUSC and LIHC. The KIRC box plot shows higher RN7SL221P RNA expression in tumor versus normal tissue (log2 FC = +0.527, t-test p < 0.001).
This table shows molecular features associated with RN7SL221P in patient tissues and cancer cell lines. In patient samples, RN7SL221P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
